Back
Redwire shares extend gains after SpaceX-linked contract and Q2 revenue beat

Redwire shares extend gains after SpaceX-linked contract and Q2 revenue beat

The aerospace company climbed further after posting record quarterly revenue and outlining a 2028 dedicated Starfall mission for SpaceMD's drug-crystallization program as ISS retirement approaches.

Fact Check
Grab's official press release directly confirms every element of the claim: it topped/reported record Q2 2026 revenue ($997M), raised full-year revenue and adjusted EBITDA guidance, and announced a new $750 million share repurchase program, with growth supported by incentives, promotions and expansion into newer services. Reuters and CNBC independently corroborate the raised outlook and buyback. The one caveat is that the large profit jump was boosted by a one-time $307M gain from Superbank consolidation, but this does not contradict the claim's summary.
    Reference: 123
Summary

Redwire shares extended gains after the company reported record second-quarter 2026 revenue and unveiled a major expansion plan for its space-based pharmaceutical business. Revenue for the quarter ended June 30 reached $117.1 million, up 89.6% from a year earlier, with gross margin improving to 27.8% from negative 30.9% in the same period of 2025. Redwire also said contracted backlog stood at $542.1 million and total liquidity at $607.8 million, including $557 million in cash. The strategic update centered on SpaceMD, Redwire's pharmaceutical subsidiary, which signed the first commercial contract for a dedicated SpaceX Starfall mission. The 2028 flight will reserve 32 PIL-BOX drug-crystallization units and, according to the company, could process more than 100 distinct drug compound experiments in a single return mission, making it the largest dedicated commercial microgravity research mission described so far. The deal was disclosed on Redwire's August 6 earnings call and marks a shift from ISS ride-along payloads toward a fully dedicated orbital manufacturing mission. SpaceMD has flown 54 PIL-BOX units to the ISS since November 2023 and says it has successfully crystallized 45 unique compounds, including insulin and drug candidates for cancer, cardiovascular disease, obesity and diabetes. The company argues microgravity can produce crystals with different or improved structural properties because sedimentation and convection are suppressed, which can affect dissolution, solubility and bioavailability. Redwire said 12 more PIL-BOX units are scheduled for ISS launches in September, October and December 2026 while SpaceMD develops a Starfall-optimized hardware variant. The Starfall mission is part of Redwire's broader push into microgravity drug development ahead of the ISS's expected retirement around 2030. NASA added $4 million in March 2026 under a $25 million five-year InSPA contract to support new pharmaceutical investigations on the ISS. Redwire CEO Peter Cannito said microgravity development is one of five key value drivers for the company, which also opened a 30,000-square-foot microgravity center of excellence in Georgetown, Indiana, on August 7, 2026.

Terms & Concepts
  • microgravity: An environment with very weak gravitational effects, allowing experiments such as crystal growth to proceed differently than on Earth.
  • drug-crystallization: The process of forming drug compounds into crystals, which can influence properties such as solubility, stability and how a medicine is absorbed.
  • contracted backlog: The value of signed business that a company expects to recognize as revenue in future periods.